Abbvie Inc

NYSE: ABBV
$176.46
-$5.04 (-2.8%)
Closing Price on December 4, 2024

ABBV Stock Chart and Intraday Price

ABBV Stock Data

Asset Type Stock
Exchange NYSE
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 316,039.17M USD
Shares Outstanding 1,766,470,000
Abbvie Inc. is a global pharmaceutical company that focuses on discovering, developing, manufacturing, and selling a wide range of treatments. Its portfolio includes therapies for autoimmune diseases, various cancers, eye diseases, neurological disorders, and more. Notable products include Humira for autoimmune conditions, Skyrizi and Rinvoq for skin and joint diseases, and Imbruvica for blood cancers. AbbVie also offers products in aesthetics, women's health, and eye care. Founded in 2012 and based in North Chicago, Illinois, AbbVie collaborates with several biotech firms to advance its research in oncology and immunology.

ABBV Articles

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Donald Trump’s victory is positive for the stock...
Companies with high dividend yields are relatively uncommon in this market. In fact, the average yield on the S&P 500 (albeit one which is heavily weighted toward tech stocks) is around 1.2%. So,...
24/7 Wall St. Insights: AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are now questioning the pharma’s pipeline, raising...
AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and reliable stock.
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct. 15th. While investors will wait to hear about quarterly earnings on Oct....
The pharmaceutical industry plays a crucial role in most of our everyday lives. From life-saving medication we need when we need it, to everyday pain remediation or allergy medications, big pharma...
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. The...
A recession is looming. Despite the S&P 500 nearing its all-time high, the yield curve inverted and the Sahm Rule was activated. The Federal Reserve is also poised to initiate the first interest...
24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential. Dividend stocks will become more popular as interest rates decline. Grab this free...
Dividend stocks can provide investors with passive long-term income.  AbbVie offers stable and consistent distributions.  Realty Income has increased its dividend for 25 consecutive years. Also: 2...
24/7 Insights Dividend Aristocrat shareholders could see some big upside in August. Looking at quality stocks that pay dependable quarterly dividends makes sense now. Also: 2 Dividend Legends to Hold...
Dividend stocks are a favorite among investors for good reasons. They provide a steady income stream and offer a promising avenue for total return. Total return, a comprehensive measure of investment...
Wall Street expectations for where Eli Lilly stock is headed this year vary considerably, but some analysts still have faith.
It defies all reason that elected officials are allowed to buy and sell stock in an economy that they are actively involved in running and are in charge of making the laws for, yet they are among the...